These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Dajas-Bailador FA, Heimala K, Wonnacott S. Mol Pharmacol; 2003 Nov; 64(5):1217-26. PubMed ID: 14573772 [Abstract] [Full Text] [Related]
3. Effects of novel tacripyrines ITH12117 and ITH12118 on rat vas deferens contractions, calcium transients and cholinesterase activity. Pereira JD, Caricati-Neto A, Miranda-Ferreira R, Smaili SS, Godinho RO, de los Rios C, Léon R, Villaroya M, Samadi A, Marco-Contelles J, Jurkiewicz NH, Garcia AG, Jurkiewicz A. Eur J Pharmacol; 2011 Jun 25; 660(2-3):411-9. PubMed ID: 21497158 [Abstract] [Full Text] [Related]
5. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. Arias E, Gallego-Sandín S, Villarroya M, García AG, López MG. J Pharmacol Exp Ther; 2005 Dec 25; 315(3):1346-53. PubMed ID: 16144975 [Abstract] [Full Text] [Related]
11. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine. Cerbai F, Giovannini MG, Melani C, Enz A, Pepeu G. Eur J Pharmacol; 2007 Oct 31; 572(2-3):142-50. PubMed ID: 17643410 [Abstract] [Full Text] [Related]
12. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Drugs Aging; 2004 Oct 31; 21(7):453-78. PubMed ID: 15132713 [Abstract] [Full Text] [Related]
14. Blockade of Ca2+ -activated K+ channels by galantamine can also contribute to the potentiation of catecholamine secretion from chromaffin cells. Alés E, Gullo F, Arias E, Olivares R, García AG, Wanke E, López MG. Eur J Pharmacol; 2006 Oct 24; 548(1-3):45-52. PubMed ID: 16949070 [Abstract] [Full Text] [Related]
15. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Schilström B, Ivanov VB, Wiker C, Svensson TH. Neuropsychopharmacology; 2007 Jan 24; 32(1):43-53. PubMed ID: 16641937 [Abstract] [Full Text] [Related]
16. Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. Kume T, Sugimoto M, Takada Y, Yamaguchi T, Yonezawa A, Katsuki H, Sugimoto H, Akaike A. Eur J Pharmacol; 2005 Dec 19; 527(1-3):77-85. PubMed ID: 16313899 [Abstract] [Full Text] [Related]
17. Dual effect of agmatine in the bisected rat vas deferens. Santos WC, Smaili SS, Jurkiewicz A, Piçarro I, Garcez-do-Carmo L. J Pharm Pharmacol; 2003 Mar 19; 55(3):373-80. PubMed ID: 12724044 [Abstract] [Full Text] [Related]
19. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Zhao Q, Tang XC. Eur J Pharmacol; 2002 Nov 29; 455(2-3):101-7. PubMed ID: 12445575 [Abstract] [Full Text] [Related]
20. Dual effect of endothelin 1 on angiotensin II-potentiated purinergic neurotransmission in prostatic rat vas deferens. Cheng M, Lee SS, Cheung WT. Eur J Pharmacol; 2007 Feb 28; 557(2-3):204-11. PubMed ID: 17196586 [Abstract] [Full Text] [Related] Page: [Next] [New Search]